CPI is partnering with Excivion Ltd Cambridge to optimize the manufacture of its novel Zika vaccine antigen candidate, Zika-HX. CPI believes that Excivion’s technology could help to prevent future pandemics of deadly viruses by avoiding the adverse immune responses common in current vaccine candidates for Zika and related viruses.   Excivion has partnered with CPI to draw upon the company’s experience in the optimization and scale-up of biologics manufacturing processes. Over the next four month...